PMID- 23706560
OWN - NLM
STAT- MEDLINE
DCOM- 20140204
LR  - 20151119
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 184
IP  - 2
DP  - 2013 Oct
TI  - Clinical-pathological implication of human leukocyte antigen-F-positive gastric 
      adenocarcinoma.
PG  - 802-6
LID - S0022-4804(13)00346-6 [pii]
LID - 10.1016/j.jss.2013.04.003 [doi]
AB  - BACKGROUND: Human leukocyte antigen (HLA)-F is a nonclassical HLA class I 
      molecule that shows aberrant expression in cancer cells. Although the clinical 
      implications of HLA-F expression in cancer patients have been described, the 
      specific significance of this antigen in gastrointestinal cancer remains unclear. 
      The present study examined the expression pattern and clinical implications of 
      HLA-F in gastric adenocarcinoma. PATIENTS AND METHODS: HLA-F expression was 
      assessed in 179 patients by immunohistochemistry, and its association with 
      clinical parameters including patient survival was analyzed. RESULTS: HLA-F 
      expression was positive in 30.7% (55/179) of patients and in 50.0% (90/179) of 
      peritumoral infiltrating lymphocytes. HLA-F expression in gastric adenocarcinoma 
      was significantly correlated with the depth of invasion, nodal involvement, and 
      lymphatic and venous invasions (P < 0.01, all). HLA-F positivity of infiltrating 
      cells near the tumor showed no correlation with clinicopathological features. 
      HLA-F-positive patients had a significantly worse prognosis than HLA-F-negative 
      patients (P = 0.012). However, HLA-F expression was not an independent prognostic 
      factor in multivariate analysis. CONCLUSIONS: The present study provides the 
      first evidence that neo-HLA-F expression is of clinical significance in gastric 
      adenocarcinoma. HLA-F expression in gastric adenocarcinoma may promote the 
      aggressive behavior of tumors by suppressing the activity of antitumor immune 
      effector cells.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ishigami, Sumiya
AU  - Ishigami S
AD  - Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University 
      School of Medicine, Kagoshima, Japan. Electronic address: 
      ishiga@m.kufm.kagoshima-u.ac.jp.
FAU - Arigami, Takaaki
AU  - Arigami T
FAU - Setoyama, Testuro
AU  - Setoyama T
FAU - Okumura, Hiroshi
AU  - Okumura H
FAU - Sasaki, Ken
AU  - Sasaki K
FAU - Uchikado, Yasuto
AU  - Uchikado Y
FAU - Kurahara, Hiroshi
AU  - Kurahara H
FAU - Kijima, Yuko
AU  - Kijima Y
FAU - Nishizono, Yuka
AU  - Nishizono Y
FAU - Nakajo, Akihiro
AU  - Nakajo A
FAU - Natsugoe, Shoji
AU  - Natsugoe S
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-F antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adenocarcinoma/*metabolism/*mortality
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Female
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - Incidence
MH  - Lymphatic Metastasis/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*metabolism/*mortality
MH  - Survival Rate
OTO - NOTNLM
OT  - Gastric adenocarcinoma
OT  - HLA-F
OT  - Infiltrating cells
OT  - Surgical outcome
EDAT- 2013/05/28 06:00
MHDA- 2014/02/05 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/12 00:00 [received]
PHST- 2013/03/27 00:00 [revised]
PHST- 2013/04/04 00:00 [accepted]
PHST- 2013/05/28 06:00 [entrez]
PHST- 2013/05/28 06:00 [pubmed]
PHST- 2014/02/05 06:00 [medline]
AID - S0022-4804(13)00346-6 [pii]
AID - 10.1016/j.jss.2013.04.003 [doi]
PST - ppublish
SO  - J Surg Res. 2013 Oct;184(2):802-6. doi: 10.1016/j.jss.2013.04.003. Epub 2013 Apr 
      26.